Press Releases

11.20.2024

Pfizer Announces New Chief Scientific Officer and President, Research & Development

11.20.2024

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

11.14.2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.04.2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

10.29.2024

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

10.23.2024

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

10.22.2024

U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

10.15.2024

Tim Buckley Elected to Pfizer’s Board of Directors

10.11.2024

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

10.10.2024

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

10.09.2024

Pfizer Declares Fourth-Quarter 2024 Dividend

10.08.2024

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024